GROSICKI, Sebastian, Maryana SIMONOVA, Ivan SPICKA,
Luděk POUR, Iryrna KRIACHOK, Maria GAVRIATOPOULOU, Halyna PYLYPENKO, Holger W AUNER, Xavier LELEU, Vadim DORONIN, Ganna USENKO, Nizar J BAHLIS, Roman HAJEK, Reuben BENJAMIN, Tuphan K DOLAI, Dinesh K SINHA, Christopher P VENNER, Mamta GARG, Mercedes GIRONELLA, Artur JURCZYSZYN, Pawel ROBAK, Monica GALLI, Craig WALLINGTON-BEDDOE, Atanas RADINOFF, Galina SALOGUB, DON, STEVENS, Supratik BASU, Anna M LIBERATI, Hang QUACH, Vesselina S GORANOVA-MARINOVA, Jelena BILA, Eirini KATODRITOU, Hanna OLIYNYK, Sybiryna KORENKOVA, Jeevan KUMAR, Sundar JAGANNATH, Phillipe MOREAU, Moshe LEVY, Darrell WHITE, Moshe E GATT, Thierry FACON, Maria V MATEOS, Michele CAVO, Donna REECE, Larry D Anderson JR, Jean-Richard SAINT-MARTIN, Jacqueline JEHA, ANITA, JOSHI, Yi CHAI, Lingling LI, Vishnuvardhan PEDDAGALI, Melina ARAZY, Jatin SHAH, Sharon SHACHAM, Michael G KAUFFMAN, MELETIOS, DIMOPOULOS, Paul G RICHARDSON a Sosana DELIMPASI. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet. New York: Elsevier, 2020, roč. 396, č. 10262, s. 1563-1573. ISSN 0140-6736. Dostupné z: https://dx.doi.org/10.1016/S0140-6736(20)32292-3.